KUALA LUMPUR: In another milestone for Malaysia, a new affordable Hepatitis C combination treatment of which clinical trials have been held in the country, has shown not only a high 97% cure rate but also better efficacy of treating the most severe form of Hepatitis.
The treatment, which uses the new drug candidate ravidasvir (in combination with a generic version of sofosbuvir) has been shown to be safe and effective, with extremely high cure rates for patients, according to interim results from the Phase II/III STORM-C-1 trial.
Already a subscriber? Log in
5.5 PAYDAY OFFER: 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
